CNS Pharmaceuticals says priority ‘is to transform’ how company operates

CNS Pharmaceuticals (CNSP) issued a Letter to Shareholders from its newly appointed President and CEO Rami Levin, which read in part, “I am honored to write to you for the first time in my role as President and Chief Executive Officer of CNS Pharmaceuticals. I have stepped into this role with deep respect for the science, the people, and the shareholders who have supported this Company to date. CNS Pharmaceuticals was founded with a vision to address life threatening diseases with a high unmet medical need, and our focus now is to pursue that mission with clarity, discipline, and a strong commitment to execution and value creation for our shareholders. Since joining CNS Pharmaceuticals as President & CEO, I have commenced a comprehensive evaluation of the company. This includes a thorough review of our pipeline, development priorities, operational structure, and capital allocation strategy. This process is not about narrowing our ambitions. It is about sharpening them with strategic intent to ensure that our Company is positioned to pursue meaningful, high-value therapeutic opportunities where we believe we can deliver real patient impact and robust long-term shareholder returns. Our evaluation will be guided by three core principles: Patients First. Every program we advance must address a serious condition with clear unmet medical need grounded in strong scientific and commercial rationale, a credible path to meaningful clinical benefit, and a realistic opportunity to improve patient outcomes. Pipeline Enrichment and Optimization. Alongside evaluating opportunities to enhance the pipeline through prioritization and business development opportunities, we are equally focused on optimizing our TPI 287 program. This includes honing the development and regulatory strategies for TPI 287 to ensure they are positioned as efficiently and effectively as possible for clinical advancement and a successful outcome. Disciplined Value Creation. We recognize the responsibility we have to our shareholders. Capital efficiency, milestone-driven execution, and transparent communication will be central to how we operate and make decisions…I firmly believe that with focus and a disciplined strategy, we can unlock our full potential and create meaningful value for patients and shareholders alike. As we move forward, our priority is to transform how CNS Pharmaceuticals operates by sharpening our focus, strengthening execution and ensuring that every decision we make is aligned with creating long-term value for our shareholders. In the near term, you can expect clear, consistent communication as we outline our strategy and demonstrate progress. We are committed to growing CNS Pharmaceuticals into a company defined by transparency, momentum and opportunity, and we believe the actions we are taking today position us well for the next phase of value creation.”